Secukinumab for Plaque Psoriasis

PASI, global assessment, and quality-of-life measures all showed efficacy.

Secukinumab is a recombinant, high-affinity, fully humanized IgG monoclonal antibody that selectively binds and neutralizes interleukin-17A (IL-17A). IL-17A is a “master cytokine” that mediates the pathogenesis of psoriasis, so neutralizing it clears psoriasis. Two new double-blind, placebo-controlled, parallel-group, phase 3 trials examined secukinumab treatment of plaque psoriasis.

ERASURE compared two injected doses of secukinumab (150 mg or 300 mg) with placebo in 738 patients; FIXTURE compared the secukinumab doses with standard doses of etanercept (50 mg twice weekly) and with placebo in 1306 patients. Investigators measured disease activity using global assessment (static 5-point scale) and the psoriasis area-and-severity index (PASI)…

Reviewing Author

Mark V. Dahl, MD

Disclosures

Consultant / Advisory board Ulthera, Inc.; AuBio LifeSciences, LLC; Paris Therapeutics

Equity Elorac, Inc.; Makucell, Inc.; Paris Therapeutics

Editorial boards UpToDate

Leadership positions in professional societiesNational Rosacea Society (Chairman, Medical Board)